Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus KEFUROX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus KEFUROX IN PLASTIC CONTAINER.
ANCEF vs KEFUROX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic